Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas

• Published in: International journal of molecular sciences Vol. 23; no. 18; p. 10215
• Main Authors: Braig, David, Runkel, Alexander, Eisenhardt, Anja E., Schmid, Adrian, Zeller, Johannes, Pauli, Thomas, Lausch, Ute, Wehrle, Julius, Bronsert, Peter, Jung, Matthias, Kiefer, Jurij, Boerries, Melanie, Eisenhardt, Steffen U.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 06-09-2022; MDPI
• Subjects: biomarker; Biomarkers; Biopsy; cfDNA; Chemotherapy; Clinical medicine; complex karyotype sarcoma; ctDNA; Genotyping; Health services; Karyotypes; liquid biopsy; Magnetic resonance imaging; Medical imaging; Mesenchyme; Metastases; Metastasis; Minimal residual disease; Mutation; Next-generation sequencing; Patients; Radiation therapy; Remission; Sarcoma; soft tissue sarcoma; Soft tissues; Tumors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms231810215

Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin with high mortality. After curative resection, about one third of patients suffer from distant metastases. Tumor follow-up only covers a portion of recurrences and is associated with high cost and radiation burden. For metastasized STS, only limited inferences can be drawn from imaging data regarding therapy response. To date there are no established and evidence-based diagnostic biomarkers for STS due to their rarity and diversity. In a proof-of-concept study, circulating tumor DNA (ctDNA) was quantified in (n = 25) plasma samples obtained from (n = 3) patients with complex karyotype STS collected over three years. Genotyping of tumor tissue was performed by exome sequencing. Patient-individual mini-panels for targeted next-generation sequencing were designed encompassing up to 30 mutated regions of interest. Circulating free DNA (cfDNA) was purified from plasma and ctDNA quantified therein. ctDNA values were correlated with clinical parameters. ctDNA concentrations correlated with the tumor burden. In case of full remission, no ctDNA was detectable. Patients with a recurrence at a later stage showed low levels of ctDNA during clinical remission, indicating minimal residual disease. In active disease (primary tumor or metastatic disease), ctDNA was highly elevated. We observed direct response to treatment, with a ctDNA decline after tumor resections, radiotherapy, and chemotherapy. Quantification of ctDNA allows for the early detection of recurrence or metastases and can be used to monitor treatment response in STS. Therapeutic decisions can be made earlier, such as the continuation of a targeted adjuvant therapy or the implementation of extended imaging to detect recurrences. In metastatic disease, therapy can be adjusted promptly in case of no response. These advantages may lead to a survival benefit for patients in the future.